Bioglutide (NA-931): what it is and what the evidence says
Promoted as an oral multi-receptor agonist. This is worth saying in the first line: there is no peer-reviewed scientific literature describing or verifying that mechanism.
Last reviewed: August 16, 2026 · How we verify this
The ground it plays on
Metabolism is not a single lever. Talk about metabolic compounds usually collapses three separate mechanisms into one word. Appetite regulation is one. How well cells respond to insulin is another, and largely independent of the first. Mobilizing stored fat is a third. A compound may act on one and leave the other two untouched, so knowing which one is the difference between understanding a molecule and reciting its name.
What it is studied for
Advertised for weight management.
There is a distinction that almost always gets lost. A compound being studied for something is not the same as achieving it. And even where it works in a dish or in a mouse, that says little about whether it works in a person or whether the benefit is worth the risk. The section below therefore carries more weight than everything above it.
What the human evidence says
There are two completed trials in people, registered by Biomed Industries: a phase 1 with 74 participants (2024) and a randomized, double-blind, placebo-controlled phase 2 lasting 13 weeks with 125 participants (2024-2025). At 2025 congresses the manufacturer reported a mean weight reduction of up to 13.8%, with nausea and vomiting in 7.3% and diarrhea in 6.3% of treated participants.
The limitation that matters most
The results are known from congress abstracts and manufacturer press releases; the full peer-reviewed article, results posted on the registry, the structure of the molecule, and its affinity for each receptor are still missing. There are also no data beyond 13 weeks, which belong to the phase 3 the manufacturer made public in 2026.
Regulatory status
Not approved by any regulatory agency in any country; it is an investigational drug whose phase 3 the manufacturer made public in 2026. It is not listed by name on the WADA list and, as a non-approved substance, it falls under section S0, prohibited at all times.
Status can change and varies by country. Always verify the rules in force where you live before drawing conclusions.
Cautions and context
No scientific publications at all. Any product sold under this name has no verifiable backing.
It is worth reviewing with a professional if you have diabetes under treatment, a history of pancreatitis, cancer, or gallbladder disease, or if you already use another drug from the GLP-1 family.
What this page cannot give you
A reference page can take you this far. You know what Bioglutide (NA-931) is and where its research stands, which already puts you ahead of most readers. Four questions remain that no encyclopedia can answer for you, because the answers depend on your own situation:
- What would you measure beforehand, so that later you could tell whether anything actually changed?
- What would you watch along the way, and how consistently?
- What would you ask a professional, and in how much detail, so you do not walk out with a textbook answer?
- What would make you stop?
That is what the course is for
PeptiXtreme is ${CIF.LECCIONES} lessons that hand out no numbers. Each one ends with your starting point, what to watch along the way, the specific questions you take to a professional and the signals that mean stop. It includes per-module exams, a Certificate of Completion with a verifiable certificate ID, a Progress Tracker to follow how you are doing, and a human advisor you can actually write to.
See the course → Or measure your judgment, freeWas this page useful?
Research moves, and when something relevant changes we update the page. If you want to hear about it for Bioglutide (NA-931) or any other compound, leave your email. The introductory guide comes with it. No spam, no list-selling; one click to unsubscribe.
Frequently asked questions
What is Bioglutide (NA-931)?
Promoted as an oral multi-receptor agonist. This is worth saying in the first line: there is no peer-reviewed scientific literature describing or verifying that mechanism. It is studied within the area of metabolic.
Is there human evidence for Bioglutide (NA-931)?
There are two completed trials in people, registered by Biomed Industries: a phase 1 with 74 participants (2024) and a randomized, double-blind, placebo-controlled phase 2 lasting 13 weeks with 125 participants (2024-2025). At 2025 congresses the manufacturer reported a mean weight reduction of up to 13.8%, with nausea and vomiting in 7.3% and diarrhea in 6.3% of treated participants.
Is it approved by any health agency?
Not approved by any regulatory agency in any country; it is an investigational drug whose phase 3 the manufacturer made public in 2026. It is not listed by name on the WADA list and, as a non-approved substance, it falls under section S0, prohibited at all times.
What is the dose of Bioglutide (NA-931)?
We do not publish dosages. This is not an oversight. No single figure works for everyone: the regimen depends on a person's medical history, on whatever medication they already take, and on the goal they are chasing, which is something a professional weighs with the case in front of them. What you can build is the ability to walk into that appointment knowing what to ask.
Where can I learn to evaluate this properly?
This page tells you what Bioglutide (NA-931) is and what the evidence says. The PeptiXtreme course teaches the other half: what you would measure before considering anything, what you would watch, the specific questions you would take to a professional and when you would stop.